Your browser doesn't support javascript.
loading
RNASeq profiling of COVID19-infected patients identified an EIF2AK2 inhibitor as a potent SARS-CoV-2 antiviral.
Jain, Sidharth; Rego, Samantha; Park, Steven; Liu, Yiran; Parn, Simone; Savsani, Kush; Perlin, David S; Dakshanamurthy, Sivanesan.
Afiliação
  • Jain S; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, District of Columbia, 20057, USA.
  • Rego S; Georgetown College, Georgetown University, Washington DC, District of Columbia, 20057, USA.
  • Park S; Georgetown College, Georgetown University, Washington DC, District of Columbia, 20057, USA.
  • Liu Y; Center for Discovery and Innovation, Hackensack Meridian Health, New Jersey, 07110, USA.
  • Parn S; Department of Biochemistry & Molecular Biology, Georgetown University Medical Center, Washington DC, District of Columbia, 20057, USA.
  • Savsani K; College of Arts & Science, University of the District of Columbia, Washington DC, District of Columbia, 20008, USA.
  • Perlin DS; College of Humanities and Sciences, Virginia Commonwealth University, Richmond, Virginia, 23284, USA.
  • Dakshanamurthy S; Center for Discovery and Innovation, Hackensack Meridian Health, New Jersey, 07110, USA.
Clin Transl Med ; 12(11): e1098, 2022 11.
Article em En | MEDLINE | ID: mdl-36321336
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article